Medical use and hemoglobinopathy
Coordinator: Dr Isabelle Redonnet (Bordeaux University Hospital)
The interest of a working group dedicated to the medical use and hemoglobinopathies associated with nitrous oxide consumption lies in the need to understand the specific effects of this substance on patients with blood disorders, as well as to explore its potential applications in medicine.
Nitrous oxide, although commonly used as an anaesthetic, can have varying impacts on individuals with haematological diseases such as haemoglobinopathies.
The main tasks of this working group are manifold:
Conduct in-depth research to document the effects of nitrous oxide consumption in patients with hemoglobinopathies.
This research will include the study of interactions between nitrous oxide and different forms of abnormal red blood cells, as well as the impact of this interaction on patient health.
Develop and standardize specific medical protocols for the use of nitrous oxide in patients with hemoglobinopathies. These protocols will help healthcare professionals administer this substance safely and effectively, minimizing the risk of complications.
Educate healthcare professionals about the potential risks and benefits of nitrous oxide use in patients with hemoglobinopathies.
Raise awareness among these professionals of best practices for managing these patients when administering nitrous oxide.
Develop clinical guidelines for the safe use of nitrous oxide in the medical setting, taking into account the particularities of patients with hemoglobinopathies. These recommendations will include advice on dosage, monitoring and management of potential side effects.
Encourage collaboration between different specialists, including hematologists, anesthesiologists, general practitioners, and medical biology researchers, for a multidisciplinary approach in the management of patients with hemoglobinopathies using nitrous oxide.
Explore the potential medical applications of nitrous oxide beyond anesthesia, notably in the treatment of pain and vaso-occlusive crises in patients with sickle cell disease and other hemoglobinopathies.
This exploration will aim to identify new therapeutic indications and improve patients' quality of life.
By fulfilling these missions, the working group will make a significant contribution to improving patient care, reducing the risks associated with nitrous oxide consumption, and promoting safer, better-informed public health.
Support the association
Would you like to participate in or propose a working group?
Fill in the form below and our teams will contact you as soon as possible.